A
Atia Vision
A privately held medical device company formed by Shifamed LLC, a Silicon Valley based medical device incubator
About Atia Vision
Atia Vision is a medical technology startup that operates in the ophthalmology market, specifically focusing on the development of advanced intraocular lenses (IOLs) for cataract patients. The company's flagship product, OmniVu™, is a modular shape-changing IOL designed to restore the full range of functional vision, from near to far, with minimal visual disturbances. This is a significant advancement over current IOLs, which often require patients to use glasses for near vision.
The company's business model revolves around the development, production, and sale of these advanced IOLs to healthcare providers and medical institutions. The OmniVu™ lens is implanted using conventional surgical techniques, making it a viable option for a wide range of patients. The lens features a unique dual-optic design, with a shape-changing, fluid-filled base and a fixed power front optic. This design aims to provide stable, predictable refractive outcomes, improving the quality of life for cataract patients.
Atia Vision's target market is vast, considering that cataracts are a common vision impairment that can lead to vision loss and blindness if left untreated. The company's innovative product addresses a significant unmet need in the market, offering a solution that provides visual correction without the side effects commonly associated with current IOLs, such as halos, glare, and difficulty seeing in dimly lit environments.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- Campbell, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 62.5/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Ophthalmology, medical implants, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Aug 2022 | $42M | $168M | Picard Angst MedTech Fund · Cormorant Asset Management · The Capital Partnership · AMED Ventures | ↗ |
| DEBTDebt | Nov 2021 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Atia Vision is 3.2K monthly website visits, up 23.1% over the last three months. Atia Vision's team declined 15% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Rising Tide Fund
Delos Capital
Series B and later5 investors entered at this stage
The Capital Partnership
Cormorant Asset Management
ShangBay Capital
AMED Ventures- PFPicard Angst MedTech Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atia Vision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atia Vision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.